Jürgen Rehm1, Allaman Allamani2, Henri-Jean Aubin3, Roberto Della Vedova4, Zsuzsanna Elekes5, Ulrich Frick6, Andrzej Jakubczyk7, Nikoleta Kostogianni3, Inga Landsmane8, Jakob Manthey9, Laia Miquel10, François Paille11, Lars Pieper12, Charlotte Probst13, Francesca Scafuri4, Kevin D Shield14, Sigita Snikere15, Pierluigi Struzzo4, Marcis Trapencieris16, Fabio Voller2, Hans-Ulrich Wittchen12, Antoni Gual10, Marcin Wojnar17. 1. Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1, Canada Addiction Policy, Dalla Lana School of Public Health, University of Toronto, 155 College Street, 6th Floor, Toronto, ON M5T 3M7, Canada Faculty of Medicine, Institute of Medical Science, University of Toronto, Medical Sciences Building, 1 King's College Circle, Room 2374, Toronto, ON M5S 1A8, Canada Department of Psychiatry, University of Toronto, 250 College Street, 8th Floor, Toronto, ON M5T 1R8, Canada Institute of Clinical Psychology and Psychotherapy & Center of Clinical Epidemiology and Longitudinal Studies (CELOS), Technische Universität Dresden, Chemnitzer Str. 46, 01187 Dresden, Germany. 2. Agenzia Regionale di Sanità Toscana, Villa la Quiete Alle Montalve, Via Pietro Dazzi 1, 50141 Firenze, Italy. 3. Centre D'Enseignement, de Recherche et de Traitement des Addictions, Hôpital Paul Brousse, AP-HP, Univ Paris-Sud, INSERM U669, 94804 Villejuif, France. 4. Regional Centre for the Training in Primary Care (Ceformed), Via Galvani 1, 34074 Monfalcone, GO, Italy. 5. Corvinus University of Budapest, Közraktár u. 4-6, H-1093 Budapest, Hungary. 6. Research Institute for Public Health and Addiction, University of Zurich, Zurich, Switzerland Department of Applied Psychology, Döpfer University of Applied Sciences, Cologne, Germany. 7. Department of Psychiatry, Medical University of Warsaw, Nowowiejska 27, 00-665 Warsaw, Poland. 8. Riga Centre of Psychiatry and Addiction Medicine, Tvaika Iela 2, Riga, Latvia. 9. Institute of Clinical Psychology and Psychotherapy & Center of Clinical Epidemiology and Longitudinal Studies (CELOS), Technische Universität Dresden, Chemnitzer Str. 46, 01187 Dresden, Germany jakobmanthey@snappyquest.org. 10. Addictions Unit, Psychiatry Department, Neurosciences Institute, Hospital Clinic, Carrer Villarroel 170, 08036, Barcelona, Spain (Catalonia) Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Carrer Rosselló 149, 08036, Barcelona, Spain (Catalonia) Red de Trastornos Adictivos (RTA - RETICS), Instituto de Salud Carlos III, Calle Sinesio Delgado, 4, 28029 Madrid, Spain (Catalonia). 11. Department of Addiction, CHU de Nancy, rue du Morvan, 54500 Vandoeuvre, France. 12. Institute of Clinical Psychology and Psychotherapy & Center of Clinical Epidemiology and Longitudinal Studies (CELOS), Technische Universität Dresden, Chemnitzer Str. 46, 01187 Dresden, Germany. 13. Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1, Canada Institute of Clinical Psychology and Psychotherapy & Center of Clinical Epidemiology and Longitudinal Studies (CELOS), Technische Universität Dresden, Chemnitzer Str. 46, 01187 Dresden, Germany. 14. Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1, Canada Faculty of Medicine, Institute of Medical Science, University of Toronto, Medical Sciences Building, 1 King's College Circle, Room 2374, Toronto, ON M5S 1A8, Canada. 15. Institute of Sociological Research, Dzirnavu Iela 55 k2-2, Riga, Latvia. 16. Institute of Sociological Research, Dzirnavu Iela 55 k2-2, Riga, Latvia Institute of Philosophy and Sociology, University of Latvia, Akademijas Laukums 1, Riga, Latvia. 17. Department of Psychiatry, Medical University of Warsaw, Nowowiejska 27, 00-665 Warsaw, Poland Department of Psychiatry, University of Michigan, 4250 Plymouth Rd, Ann Arbor, MI 48109, USA.
Abstract
AIM: To provide a description of patients receiving alcohol treatment in eight different European countries, including the level of comorbidities and functional limitations. METHODS: Drinking behaviours, DSM-IV alcohol use disorder (AUD), mental and somatic comorbidities, disability and health services utilization of 1767 patients from various specialized treatment settings were assessed as representative for regions of eight European countries. Severity of alcohol dependence (AD) in terms of drinking level was compared with a large representative US sample. RESULTS: Patients in specialized care for AUDs showed high levels of consumption [average level of daily ethanol intake: 141.1 g, standard deviation (SD): 116.0 g], comorbidity [e.g. liver problems: 19.6%, 95% confidence interval (CI): 17.5-21.6%; depression: 43.2%, 95% CI: 40.7-45.8%; anxiety: 50.3%, 95% CI: 47.8-52.9%], disability and health services utilization (average number of nights spent in hospital(s) during the last 6 months: 8.8, SD: 19.5 nights). Severity of AD was similar to the US sample, but European men consumed on average more alcohol daily. CONCLUSIONS: High levels of consumption, somatic and mental comorbidities, disability and functional losses were found in this representative treatment sample, indicating that treatment was initiated only at severe stages of AUDs. Earlier initiation of treatment could help avoid some of the health and social burden.
AIM: To provide a description of patients receiving alcohol treatment in eight different European countries, including the level of comorbidities and functional limitations. METHODS: Drinking behaviours, DSM-IV alcohol use disorder (AUD), mental and somatic comorbidities, disability and health services utilization of 1767 patients from various specialized treatment settings were assessed as representative for regions of eight European countries. Severity of alcohol dependence (AD) in terms of drinking level was compared with a large representative US sample. RESULTS:Patients in specialized care for AUDs showed high levels of consumption [average level of daily ethanol intake: 141.1 g, standard deviation (SD): 116.0 g], comorbidity [e.g. liver problems: 19.6%, 95% confidence interval (CI): 17.5-21.6%; depression: 43.2%, 95% CI: 40.7-45.8%; anxiety: 50.3%, 95% CI: 47.8-52.9%], disability and health services utilization (average number of nights spent in hospital(s) during the last 6 months: 8.8, SD: 19.5 nights). Severity of AD was similar to the US sample, but European men consumed on average more alcohol daily. CONCLUSIONS: High levels of consumption, somatic and mental comorbidities, disability and functional losses were found in this representative treatment sample, indicating that treatment was initiated only at severe stages of AUDs. Earlier initiation of treatment could help avoid some of the health and social burden.
Authors: Moayad Mustafa Hejazi; Ala Osman Bacha; Mohammed Kaleemuddin; Fahad A Al-Abassi; Abdulbasit I Al-Alsieni; Imran Kazmi; Firoz Anwar Journal: Mol Cell Biochem Date: 2017-12-16 Impact factor: 3.396
Authors: Meyer D Glantz; Chrianna Bharat; Louisa Degenhardt; Nancy A Sampson; Kate M Scott; Carmen C W Lim; Ali Al-Hamzawi; Jordi Alonso; Laura Helena Andrade; Graca Cardoso; Giovanni De Girolamo; Oye Gureje; Yanling He; Hristo Hinkov; Elie G Karam; Georges Karam; Viviane Kovess-Masfety; Victor Lasebikan; Sing Lee; Daphna Levinson; John McGrath; Maria-Elena Medina-Mora; Constanta Mihaescu-Pintia; Zeina Mneimneh; Jacek Moskalewicz; Fernando Navarro-Mateu; José Posada-Villa; Charlene Rapsey; Juan Carlos Stagnaro; Hisateru Tachimori; Margreet Ten Have; Nathan Tintle; Yolanda Torres; David R Williams; Yuval Ziv; Ronald C Kessler Journal: Addict Behav Date: 2019-09-16 Impact factor: 3.913
Authors: A Luquiens; D Whalley; P Laramée; B Falissard; N Kostogianni; J Rehm; J Manthey; F Paille; H J Aubin Journal: Qual Life Res Date: 2015-11-20 Impact factor: 4.147
Authors: Michaël Schwarzinger; Sophie Pascale Thiébaut; Sylvain Baillot; Vincent Mallet; Jürgen Rehm Journal: BMC Public Health Date: 2017-07-21 Impact factor: 3.295
Authors: Icro Maremmani; Mauro Cibin; Pier Paolo Pani; Alessandro Rossi; Giuseppe Turchetti Journal: Int J Environ Res Public Health Date: 2015-11-19 Impact factor: 3.390